Articles by Rita Peters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Rita Peters

Rita Peters

Editorial Director

Articles
Benefits and Risks of Drug Information on Social Media
July 2, 2014

FDA draft guidances seek to maintain accurate drug information for patients in new media.

US Biopharma Worries About Losing Lead in Innovation
May 2, 2014

Changes are needed to maintain US biopharma innovation leadership.

Biopharma Takes a Nervous Glance Over Its Shoulder
May 2, 2014

Changes are needed to maintain US biopharma innovation leadership.

Publishing Beyond the Printed Page
April 2, 2014

More media options open publishing opportunities for drug development experts.

Defining Quality Metrics is No Easy Task
February 2, 2014

ISPE and PDA take on the challenge of recommending quality metrics.

2014 Manufacturing Trends and Outlook
January 15, 2014

A survey of BioPharm International readers found that single-use systems and other technologies are driving process efficiencies in biomanufacturing, but there is room for improvement.

New Dynamics in Drug Pricing and Prescribing
January 3, 2014

Generics, market dynamics, and global demand are changing drug-spending patterns.

Drugs At What Cost
January 2, 2014

Generics, market dynamics, and global demand are changing drug spending patterns.

Uncertainty in the Workplace
December 2, 2013

Industry mergers, acquisitions and downsizing contribute to uncertainty in job security in the European bio/pharmaceutical market.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here